| Old Articles: <Older 4711-4720 Newer> |
|---|
 |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan.   |
The Motley Fool
April 1, 2008
Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool
April 1, 2008
Brian Lawler |
Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere. |
The Motley Fool
April 1, 2008
Brian Lawler |
VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market. |
The Motley Fool
April 1, 2008
Brian Lawler |
The Endo a Patent? Endo sues to protect a lead drug from generic competition. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Little Up Front and a Lot Later for Cell Genesys Small development-stage drugmaker Cell Genesys announces that it has inked a partnership deal for its lead drug with pharmaceutical giant Takeda. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
March 31, 2008
Brian Lawler |
Corcept's Devotion to Its Lead Drug Corcept Therapeutics will try again with its compound for psychotic depression. |
The Motley Fool
March 31, 2008
Brian Lawler |
FDA Commish Joins Blogosphere Andrew von Eschenbach, the FDA's chief, starts a weekly blog. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
| <Older 4711-4720 Newer> Return to current articles. |
